The combination of SRA737, an oral CHK1 inhibitor, with or without anti–PD-L1/anti-PD-1 leads to an antitumor response in multiple cancer models, including Small Cells Lung Cancer (SCLC). Here, CHEK1 is linked to small cell lung carcinoma.